Pharma Equity Group A/S (CPH: PEG)
Denmark
· Delayed Price · Currency is DKK 0.174
+0.005 (2.65%)
Dec 20, 2024, 3:43 PM CET
Pharma Equity Group Company Description
Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement.
Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma.
The company was incorporated in 2002 and is based in Hørsholm, Denmark.
Pharma Equity Group A/S
| Country | Denmark |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Thomas Selsø |
Contact Details
Address: Slotsmarken 18, 2. th. Horsholm, 2970 Denmark | |
| Phone | 45 41 92 25 25 |
| Website | pharmaequitygroup.com |
Stock Details
| Ticker Symbol | PEG |
| Exchange | Copenhagen Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | DKK |
| ISIN Number | DK0061155009 |
| SIC Code | 6799 |
Key Executives
| Name | Position |
|---|---|
| Thomas Kaas Selsø | Chief Executive Officer |
| Martin Engell-Rossen | Head of Cabinet |
| Peter Ekman | Financial Manager |
| Lars Skriver | Chief Operations Officer |
| Pernille Lyngholm | Chief Business Development Officer |
| Dr. Lars Otto Uttenthal | Chief Medical Officer |